sales of Namenda
were $929M, according to December 2017 QuintilesIMS market data.
For intervention, a treatment with a Cholinesterase inhibitor as well as a glutamatergic agent (NMDA receptor antagonist), including Aricept and Namenda
, can be used for this form of Alzheimer's disease.
36) The brand's internal documents in the hearing in the Namenda
case discussed below revealed that "if we do the hard switch and  convert patients and caregivers to once-a-day therapy versus twice a day, it's very difficult for the generics then to reverse-commute back.
Aricept (donepezil hydrochloride) from Pfizer/Eisais was the world best-selling drug till 2010, which lost patent protection in November 2010 and at present, Namenda
(memantine hydrochloride) from Forest Laboratories, Exelon (rivastigmine) from Novartis and Ebixa (memantine) from Lundbeck Ltd.
The company said the Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, is the therapeutic equivalent to the reference listed drug, Namenda
Tablets, 5 mg and 10 mg, of Forest Laboratories LLC.
Clinical studies have shown that combination therapy with Namenda
XR and an AChEI such as Aricept demonstrated significantly superior improvement in cognition and global function verses an AChEI alone.
XR revenues in the first quarter of 2016 were $173 million, up 15%.
4) The court held that Actavis' withdrawal of Namenda
IR from the market violated the Sherman Act because its actions effectively amounted to coercion by impeding generic competition and limiting consumer options.
Allergan, best known for its anti-wrinkle treatment Botox, also makes Alzheimer's drug Namenda
and dry-eye medication Restasis.
LUPIN'S RECENT GENERIC LAUNCHES BRAND EQUIVALENT Memantine HCI Tablets USP Namenda
Bimatoprost Ophthalmic Solution 0.
The attorney-general of New York, Eric Schneiderman, won a preliminary injunction to stop the drug company Actavis and its subsidiary Forest Laboratories from withdrawing an older version of Namenda
, a drug to treat moderate-to-severe Alzheimer's disease with a patent that expires in July, and replacing it with a newer version covered by a patent that would extend until 2029.
The company claims the litigation by New York Attorney General Eric Schneiderman would hurt it, as it moves forward to offer the medication, Namenda
XR, to treat Alzheimer's disease.